FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)|BIOLOGICAL: Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.